Ondine Biomedical Inc. (LON:OBI) Insider Purchases C$1,939,925.00 in Stock

Ondine Biomedical Inc. (LON:OBI) insider Carolyn Cross bought 149,225 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The stock was acquired at an average cost of C$13.00 per share, for a total transaction of C$1,939,925.00.

Carolyn Cross also recently made the following trade(s):

• On Thursday, January 30th, Carolyn Cross acquired 200,775 shares of Ondine Biomedical stock. The stock was acquired at an average price of C$12.00 per share, with a total value of C$2,409,300.00.

Ondine Biomedical Price Performance

OBI opened at C$12.50 on Friday. The company has a debt-to-equity ratio of 1,847.37, a quick ratio of 8.26 and a current ratio of 0.80. The stock has a market capitalization of C$3.47 billion, a PE ratio of -416.67 and a beta of 0.10. The stock’s 50 day moving average price is C$9.52 and its 200-day moving average price is C$8.10. Ondine Biomedical Inc. has a 52-week low of C$4.50 and a 52-week high of C$13.30.

Ondine Biomedical Company Profile

Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens.

Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings.